|
Repurposing a Potent MDM2 Inhibitor for Leukemia Treatment
Application
VERU-111, also known as sabizabulin, is a potent microtubule inhibitor and, notably, an MDM2 inhibitor. This repurposed compound demonstrates remarkable efficacy in the treatment of Acute Myeloid Leukemia (AML).
Key Benefits
Unique dual-action functionality as a microtubule and MDM2 inhibitor.
Successful inhibition of MDM2, an oncogene...
Published: 2/13/2025
Updated: 8/5/2024
Inventor(s): Deborah DeRyckere, Muxiang Zhou, Lu Bing Gu, Douglas Graham, Tao Liu
|
|
ONC201 for the Treatment of Vascular Aneurysms
Application
A repurposed therapeutic for the preventative and treatment of aneurysms.
Key Benefits
A repurposed cancer drug that targets cells known to be damaged during the progression of an aneurysm.
The drug has been tested within an animal model of aortic aneurysms, where it prevented the severe complications of the disease and protected the...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Alejandra Maria San Martin
|
|
Therapeutic to Treat Age-Dependent Idiopathic Pulmonary Fibrosis
Application
Therapeutic for treating age-associated lung fibrosis.
Key Benefits
Tecfidera (dimethyl fumarate - DMF) is an FDA approved therapy to treat multiple sclerosis via oral administration.
A novel formulation for inhaled delivery demonstrated efficacy for a new indication: Idiopathic Pulmonary Fibrosis (IPF), where it promotes the reversal...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Louise Hecker, Kosuke Kato, Priyadarshini Muralidharan, Heidi Mansour
|
|
Repurposed Treatment for Cocaine Use Disorder
Application
Repurposed drug for transcriptomic-driven treatment of cocaine use disorder.
Key Benefits
FDA-approved drug.
Outperformed current targets undergoing clinical trials for CUD at the mRNA level.
Market Summary
Cocaine abuse is associated with substantial morbidity and mortality, and there are no approved medications for the treatment...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Rohan Palmer, Spencer Huggett
|
|
Combination of Tetrahydrobiopterin and Arginine/ ± Arginase Inhibitors for the Treatment of COVID-19
Application
A novel drug combination to address acute arginine/BH4 dysregulation that develops with COVID-19 and MIS-C infection.
Key Benefits
Potential to improve outcomes of those infected with COVID-19 with few side effects.
Repurposing opportunity with the combination of two approved drugs (tetrahydrobiopterin and arginine).
Addresses...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Claudia Morris, Lou Ann Brown
|
|
Drug Combination to Treat Lung Cancer Metastasis
Application
Combination product co-targeting PDH and GLUT1 to inhibit lung cancer metastasis.
Key Benefits
Combination of drugs exhibits greater synergism in cancer cell lines (H1299, 4T1, H1792).
Has potential to prevent metastasis in a variety of cancers.
Decreases both cell viability and invasive area.
Repurposed drugs.
Market Summary
Metastatic...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Malathy (Mala) Shanmugam, Adam Marcus
|
|
Targeted Anti-Cancer Nanoparticle Therapy
Application
A drug-carrying nanoparticle that selectively targets cancer cells.
Key Benefits
Incorporates an already proven anti-cancer therapeutic.
Increases deliverability.
Targets cancer cells.
Market Summary
Tris DBA palladium has been shown to have anti-cancer activity against melanoma and pancreatic cancer. However, Tris DBA has not...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Jack Arbiser, Lily Yang
|
|
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application
Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages.
Key Benefits
Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi.
Relatively low regulatory risk because many...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Young-Sup Yoon, Ji Woong (Jay) Han, Hyunsuk Shim
|
|
DHAA and Derivatives for Treatment of BRAF-V600E-Positive Cancer
Application
Hypolipidemic dehydroacetic acid (DHAA) treatment to prevent growth of BRAF V600E positive tumors.
Key Benefits
Treatment with slows BRAF V600E-positive tumor growth.
Repurposed compound may speed FDA approval.
May be used in combination with other therapies.
Market Summary
Up to 50% of melanoma cases harbor the BRAF V600E mutation,...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Jing Chen, Jack Arbiser, Brian Pollack, Siyuan Xia
|
|
Repurposed Kinase Inhibitor for Treatment of Multidrug Resistant Tuberculosis
ApplicationProtein tyrosine kinase inhibitor (imatinib) used as a treatment to prevent multiple drug-resistant tuberculosis lethality and latent reactivation.Key BenefitsEffective against drug resistant strains of tuberculosis.May be used in combination with current first-line treatments of TB.Market SummaryTuberculosis (TB) is a chronic infectious...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Daniel Kalman
|
